151.22 USD
▼-0.47-0.31%
盘后 151.20 -0.01%
2026-09-15
市值
$2.18B
市盈率
—
EPS
-4.90
股息率
—
52 周区间
53.30 – 161.38
成交量
215.61K
Beta
—
目标价
230.53
52W 低 53.3052W 高 161.38
价格走势
公司简介
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ...